The key is ensuring deep and massive purification of the blood
For generations, dialysis has held the line between life and death for those whose kidneys have failed — yet the line has always been imperfect, leaving behind the heavier burdens of disease. In Chile, a more thorough approach called High-Volume Hemodiafiltration is beginning to redefine what it means to treat kidney failure, not merely survive it. By removing the molecular waste that conventional machines cannot reach, HvHDF offers something rarer than longevity: the possibility of a life that feels worth living.
- Conventional dialysis has long masked a quiet failure — it keeps patients alive while allowing larger uremic toxins to accumulate, fueling inflammation and cardiovascular mortality rates that rival some cancers.
- HvHDF applies active hydraulic pressure to pull out the toxins that standard filtration misses, functioning less like a passive screen and more like a thorough cleansing of the bloodstream.
- The most vulnerable — children, pregnant women, and patients destabilized by conventional treatment — are first in line, as the stakes of inadequate purification are highest for them.
- Chilean specialists estimate that between 2,500 and 3,100 dialysis patients could qualify for priority access, but expanding that access equitably remains the defining challenge ahead.
For decades, dialysis has been the lifeline for people whose kidneys no longer function — but doctors in Chile have begun confronting an uncomfortable truth: the machines are leaving something behind. Conventional dialysis removes small toxins efficiently, yet the heavier molecular waste continues to circulate, triggering chronic inflammation, arterial damage, and heart attack rates that rival some cancers. The treatment sustains life, but often fails to restore it.
High-Volume Hemodiafiltration, or HvHDF, takes a more forceful approach. Rather than passively filtering blood, it uses active hydraulic pressure — continuously infusing ultrapure replacement fluid while drawing out the larger toxins conventional machines cannot reach. The clinical results are meaningful: fewer hospitalizations, fewer cardiac events, and a better quality of life between sessions. Dr. Cristian Pedreros of Hospital Las Higueras in Talcahuano frames it plainly — the goal is not a better machine, but deeper, more thorough purification of the blood.
Priority access is being directed toward those with the most to lose: children and adolescents, for whom early cardiovascular damage can define an entire lifetime; pregnant women on dialysis, where both maternal and fetal risk are extreme; and patients who suffer severe episodes of low blood pressure, nausea, or cramping during conventional sessions. Those living with chronic complications — malnutrition, joint deterioration, persistent insomnia, unrelenting itching — are also strong candidates.
Specialists estimate that roughly 10 to 12 percent of Chile's dialysis population, between 2,500 and 3,100 people, could qualify for HvHDF under priority criteria. The therapy's effectiveness is no longer in question. What remains is the harder work: building the infrastructure and will to reach everyone who needs it.
For decades, dialysis has been the lifeline for people whose kidneys no longer work. Millions depend on it. But doctors across Chile have begun to acknowledge a stubborn problem: the machines doing the filtering are leaving something behind.
Conventional dialysis removes small toxins from the blood efficiently enough. But medium and large uremic toxins—the heavier molecular waste that accumulates when kidneys fail—slip through. These substances linger in the bloodstream, triggering chronic inflammation, scarring arteries, and driving up the risk of heart attacks. The result is mortality rates among dialysis patients that rival some cancers. The treatment keeps people alive, but it doesn't keep them well.
A more aggressive approach is gaining ground: High-Volume Hemodiafiltration, or HvHDF. Where conventional dialysis works passively, filtering blood like water through a screen, HvHDF deploys active hydraulic pressure—more like a pressure washer for blood. The system continuously infuses ultrapure replacement fluid while the pressure does the work, pulling out the larger toxins that conventional machines miss. When the volume of fluid exchanged per session stays high, the results can be substantial: fewer heart attacks, fewer hospitalizations, better recovery between treatments.
Dr. Cristian Pedreros, a nephrologist at Hospital Las Higueras in Talcahuano, emphasizes that the difference isn't just about having a fancier machine. "The key is ensuring deep and massive purification of the blood," he explains. That capacity—that thoroughness—is what separates basic life support from therapy that actually improves how patients live day to day.
Not everyone on dialysis can access HvHDF yet, and not everyone needs it equally. Children and adolescents under fifteen are a priority group; the therapy can prevent the cumulative cardiovascular damage that would otherwise shadow their entire lives and support better physical and nutritional development. Pregnant women on dialysis qualify as well—a scenario of extreme maternal and fetal risk where the cardiovascular stability HvHDF provides becomes critical.
Patients who struggle with conventional dialysis also move to the front of the line: those who experience sudden blood pressure drops, severe dizziness, nausea, or muscle cramps during sessions. And those carrying the weight of chronic complications—malnutrition driven by persistent inflammation, severe joint pain, amiloidosis, resistant insomnia, relentless itching—stand to gain significantly from the deeper toxin removal.
Currently, specialists estimate that between 2,500 and 3,100 Chileans on chronic dialysis—roughly 10 to 12 percent of the total dialysis population—could qualify for priority access to HvHDF. Each case requires individual clinical evaluation by specialized teams. The challenge now is not whether the therapy works, but whether the country can expand access widely enough to reach those who need it most. The goal is no longer just to extend life, but to make that life livable.
Citações Notáveis
The key is ensuring deep and massive purification of the blood. That capacity is what marks the difference between basic support and therapy that truly improves quality of life.— Dr. Cristian Pedreros, nephrologist at Hospital Las Higueras de Talcahuano
A Conversa do Hearth Outra perspectiva sobre a história
Why does conventional dialysis leave these medium and large toxins behind? Isn't the whole point to clean the blood?
It's a matter of physics. Conventional dialysis relies on diffusion—toxins naturally migrate across a membrane toward cleaner fluid. But the larger molecules move slowly, and they don't cross the membrane as easily. The system works well for small waste, but it's fundamentally passive. It can't pull out what won't naturally drift across.
And HvHDF solves that by using pressure instead?
Exactly. Active hydraulic force doesn't wait for molecules to drift. It pushes them across. It's more aggressive, more complete. The continuous infusion of ultrapure fluid also protects the patient while that deeper cleaning happens.
So why isn't everyone on HvHDF already?
Cost, complexity, and the fact that not everyone needs it. If you're stable on conventional dialysis, the risks of switching may outweigh the benefits. But if you're a child whose arteries are accumulating damage, or a pregnant woman whose body is under extreme stress, or someone whose conventional sessions leave you cramping and dizzy—then HvHDF becomes essential.
How many people in Chile are we talking about?
Between 2,500 and 3,100 people could benefit from priority access. That's roughly one in ten dialysis patients. It's significant, but it also means the system needs to expand carefully, with clinical teams evaluating each person individually.
What happens if they don't get access?
They continue on conventional dialysis, managing the symptoms—the inflammation, the cardiovascular risk, the poor quality of life—as best they can. The therapy exists. The question is whether the country can make it available.